The potential for tumor suppressor gene therapy in head and neck cancer

Andrew Birkeland, Megan L. Ludwig, Matthew E. Spector, J. Chad Brenner

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Head and neck squamous cell carcinoma remains a highly morbid and fatal disease. Importantly, genomic sequencing of head and neck cancers has identified frequent mutations in tumor suppressor genes. While targeted therapeutics increasingly are being investigated in head and neck cancer, the majority of these agents are against overactive/overexpressed oncogenes. Therapy to restore lost tumor suppressor gene function remains a key and under-addressed niche in trials for head and neck cancer. Recent advances in gene editing have captured the interest of both the scientific community and the public. As our technology for gene editing and gene expression modulation improves, addressing lost tumor suppressor gene function in head and neck cancers is becoming a reality. This review will summarize new techniques, challenges to implementation, future directions, and ethical ramifications of gene therapy in head and neck cancer.

Original languageEnglish (US)
JournalDiscovery Medicine
Issue number113
StatePublished - Jan 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The potential for tumor suppressor gene therapy in head and neck cancer'. Together they form a unique fingerprint.

Cite this